Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

MT newswireMT newswire2026/09/02 11:35
07:35 AM EDT, 09/02/2026 (MT Newswires) -- Novartis (NVS) has signed an option and licensing agreement with South Korean biotech Alteogen to develop and sell subcutaneous versions of multiple Novartis drugs using its ALT-B4 technology, Alteogen said Wednesday. The company said ALT-B4 is designed to convert biologic medicines typically given through intravenous infusions into faster injections under the skin. If Novartis exercises all options and all milestones are met, Alteogen could receive up to $3.223 billion, including option fees, development and commercial milestones, and royalties on product sales, it added.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share

Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

华尔街见闻•2026/11/21 12:01
Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share